Category Archives: Novartis Case

SURPRISE! BIG PHARMA DON’T WANT DEVELOPING COUNTRIES HAVING ACCESS TO CHEAP MEDICINE

Source: http://www.vice.com Compared to a number of other nations, India has done an incredible job of keeping medicine cheap enough that its citizens can afford to buy whatever it is that they need. Most importantly, it avoids handing out patents … Continue reading

Posted in Compulsory Licensing, Indian Patent Law, Novartis Case, patent evergreening, Sec 3 (d), TRIPS flexibilities | Leave a comment

“Novartis and the Battle to Access Essential Drugs”

Source: Newsclick This feature examines why India’s patenting regime, despite being pro-public in terms of promoting easier access to drugs, has faced considerable criticism, particularly post the Supreme Court decision in the Novartis case. The feature examines why India has … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Novartis Case, patent, patent evergreening, Patent examination system, Sec 3 (d), TRIPS, WTO | Leave a comment

Lawyers Collective Response to Testimony of Mr. Roy F Waldron, Pfizer Inc.

Source: Lawyers Collective Recently, several multinational pharmaceutical companies along with the US Chamber of Commerce have been instrumental in mounting pressure on India to decry the alleged state of Intellectual Property (IP) regime in India. On June 27, 2013 a … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, IP Rights, Novartis Case, patent, Patent examination system, Right to Health, Sec 3 (d) | Tagged , , | Leave a comment

IPA response to Pfizer’s letter

IPA’s response to Pfizer letter of 23 May 2013 and Testimony before the Subcommittee on Commerce, Manufacturing and Trade of the House Committee of Energy and Commerce on 27 June 2013. Acces the letter here

Posted in access to medicines, Generic drug, IP Rights, IPR Enforcement, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TRIPS, WTO | Leave a comment

Indian Pharmaceutical Alliance slams US over charges on Indian patent law

Source: Economic Times NEW DELHI: Indian Pharmaceutical Alliance (IPA) has contested US allegations that India’s patent Act is discriminatory and said America can go to WTO’s dispute settlement mechanism if such is the case. An industry body comprising mainly domestic … Continue reading

Posted in access to medicines, Drug Pricing, IP Rights, IPR Enforcement, Novartis Case, patent, patent evergreening, Patent examination system, Right to Health, Sec 3 (d), TRIPS, WTO | Tagged , , | Leave a comment

Engineered in India — Patent Law 2.0

Source: New England Journal of Medicine Amy Kapczynski, J.D. July 17 2013 India is known as the “pharmacy of the developing world,” because it supplies much of the world’s demand for affordable, generic drugs. So when the Supreme Court of … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, IP Rights, Novartis Case, patent, Right to Health, Sec 3 (d) | Leave a comment

A victory for access to medicines

Source:TWN The Indian Supreme Court’s 1 April decision which reaffirmed that only medicines that are genuinely new inventions should be granted patents has been hailed as a victory for the rights of patients to have affordable medicines.   Martin Khor PATIENTS … Continue reading

Posted in access to medicines, Generic drug, IP Rights, Novartis Case, patent, Sec 3 (d), TRIPS | Tagged | Leave a comment